DE60235178D1 - Darreichungsformen mit verlängerter wirkstofffreisetzung - Google Patents

Darreichungsformen mit verlängerter wirkstofffreisetzung

Info

Publication number
DE60235178D1
DE60235178D1 DE60235178T DE60235178T DE60235178D1 DE 60235178 D1 DE60235178 D1 DE 60235178D1 DE 60235178 T DE60235178 T DE 60235178T DE 60235178 T DE60235178 T DE 60235178T DE 60235178 D1 DE60235178 D1 DE 60235178D1
Authority
DE
Germany
Prior art keywords
active ingredient
pharmaceutical forms
oral administration
extended active
daily oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60235178T
Other languages
English (en)
Inventor
Peter Truog
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lunamed AG
Original Assignee
Lunamed AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lunamed AG filed Critical Lunamed AG
Application granted granted Critical
Publication of DE60235178D1 publication Critical patent/DE60235178D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DE60235178T 2001-09-10 2002-09-04 Darreichungsformen mit verlängerter wirkstofffreisetzung Expired - Lifetime DE60235178D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01810865A EP1291015A1 (de) 2001-09-10 2001-09-10 Darreichungsformen mit verlängerter Wirkstofffreisetzung
PCT/CH2002/000486 WO2003022253A1 (de) 2001-09-10 2002-09-04 Dosage forms having prolonged active ingredient release

Publications (1)

Publication Number Publication Date
DE60235178D1 true DE60235178D1 (de) 2010-03-11

Family

ID=8184126

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60235178T Expired - Lifetime DE60235178D1 (de) 2001-09-10 2002-09-04 Darreichungsformen mit verlängerter wirkstofffreisetzung

Country Status (13)

Country Link
US (1) US7611729B2 (de)
EP (2) EP1291015A1 (de)
JP (1) JP2005508901A (de)
CN (1) CN100508965C (de)
AT (1) ATE455539T1 (de)
AU (1) AU2002322964B2 (de)
CA (1) CA2459165C (de)
DE (1) DE60235178D1 (de)
DK (1) DK1427396T3 (de)
ES (1) ES2339536T3 (de)
HK (1) HK1071847A1 (de)
PT (1) PT1427396E (de)
WO (1) WO2003022253A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1291015A1 (de) 2001-09-10 2003-03-12 Lunamed AG Darreichungsformen mit verlängerter Wirkstofffreisetzung
US20070004805A1 (en) * 2005-07-01 2007-01-04 Navinta Llc Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
CN101263121A (zh) 2005-07-14 2008-09-10 塔克达圣地亚哥公司 组蛋白脱乙酰基酶抑制剂
US20070202164A1 (en) * 2006-02-28 2007-08-30 Hutchison Medipharma Enterprises Limited Andrographis Extract Formulations
FR2959129B1 (fr) * 2010-04-21 2013-02-01 Lucane Pharma Particules comprenant du 4-phenylbutyrate de sodium, procede de preparation et utilisations
EP2389932A1 (de) 2010-05-28 2011-11-30 Lunamed AG Zusammensetzungen zur Verwendung bei Erbkrankheiten, die 4-Phenylbuttersäure und deren Salze umfassen
EP2397458A1 (de) 2010-06-21 2011-12-21 Lunamed AG Organische Salze und Co-Kristalle von Phenylbuttersäure
EP2599477A1 (de) 2011-11-30 2013-06-05 Lunamed AG Verzögerte Freisetzungsformulierung mit 4-Phenylbuttersäure
EP2599482A1 (de) * 2011-11-30 2013-06-05 Lunamed AG Therapeutische Verwendung von niedrig dosiertem Glyceryl Tri-(4-Phenylbutyrat)
EP2599483A1 (de) 2011-11-30 2013-06-05 Lunamed AG 4-Phenylbuttersäure-Formulierung
EP2599767A1 (de) 2011-11-30 2013-06-05 Lunamed AG Phenylbutyl-Derivate
EP2599481A1 (de) * 2011-11-30 2013-06-05 Lunamed AG 4-Phenylbuttersäure zur Behandlung oder Vorbeugung von verschiedenen Erkrankungen
EP2607367A1 (de) 2011-12-21 2013-06-26 Lunamed AG Glycerol-Phenyl-Butyrat-Derivate
EP2607366A1 (de) 2011-12-21 2013-06-26 Lunamed AG Glycerol-Phenyl-Butyrat-Ester
EP2698156A1 (de) 2012-08-16 2014-02-19 Lunamed AG Phenylbutyrensäure zur Chemoprävention
EP2698155A1 (de) * 2012-08-16 2014-02-19 Lunamed AG Pharmazeutische Dosierungseinheit enthaltend 4-Phenylbuttersäure
RU2635539C2 (ru) * 2016-03-10 2017-11-13 Федеральное государственное бюджетное учреждение науки Институт высокомолекулярных соединений Российской академии наук Полимерные водорастворимые производные 4-фенил-бутановой кислоты, обладающие противоопухолевой активностью
HUE059630T2 (hu) 2016-03-15 2022-11-28 Acer Therapeutics Inc Nátrium-fenil-butirátot tartalmazó, kellemes ízû készítmények és alkalmazásaik
CN106109429A (zh) * 2016-07-26 2016-11-16 北京百奥药业有限责任公司 一种苯丁酸钠片剂及其制备方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
EP0567613B1 (de) * 1991-10-21 2002-02-20 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Zusammensetzungen zur behandlung und vorbeugung von krebs
US5635532A (en) 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
US6037376A (en) 1991-10-21 2000-03-14 The United States Of America As Represented By The Department Of Health And Human Services Methods for therapy of cancer
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
AU7973994A (en) 1993-10-13 1995-05-04 Merck & Co., Inc. Combination therapy for hiv infection
US5569680A (en) 1995-02-13 1996-10-29 Trustees Of The Univ. Of Penna Method of treating inflammatory bowel disease with tributyrin
US6011000A (en) 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
US5912269A (en) 1996-04-30 1999-06-15 Vertex Pharmaceuticals, Inc. Butyrate prodrugs derived from lactic acid
US5763488A (en) 1995-10-30 1998-06-09 Vertex Pharmaceuticals Incorporated Methods and compositions using butyrate esters of threitol
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US5939455A (en) 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
JP2002506436A (ja) * 1997-06-13 2002-02-26 ザ ジョンズ ホプキンス ユニバーシティー 治療用ナノスフェア
US5972995A (en) 1997-10-16 1999-10-26 Children's Hospital Medical Center Of Northern California Compositions and methods for cystic fibrosis therapy
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US6262116B1 (en) 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
AU6269799A (en) * 1998-09-28 2000-04-17 Johns Hopkins University, The Adrenoleukodystrophy treatments and drug screening
JP2002539227A (ja) * 1999-03-19 2002-11-19 バーテックス ファーマシューティカルズ インコーポレイテッド 経口低用量ブチレート組成物
US6403646B1 (en) 1999-06-30 2002-06-11 David H. Perlmutter Method for the treatment of alpha-1-antitrypsin deficiency and related pathologies
WO2001041707A2 (en) 1999-12-08 2001-06-14 Vanderbilt University Modulation of in vivo glutamine and glycine levels in the treatment of autism
US6656912B2 (en) 2000-01-20 2003-12-02 Washington University In St. Louis Methods to treat α1-antitrypsin deficiency
FR2810547B1 (fr) 2000-06-22 2004-01-30 Pasteur Institut Utilisation d'acides en c2-c10 pour la prevention des infections a bacteries a gram negatif
US6987131B1 (en) 2000-06-26 2006-01-17 Burzynski Stanislaw R Phenylacetic acid compositions for treating or preventing hypercholesterolemia
US20020115619A1 (en) * 2000-10-04 2002-08-22 Rubenstein Ronald C. Compositions and methods for treatment of cystic fibrosis
AU2002243231A1 (en) 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases
JP2004537275A (ja) 2001-01-16 2004-12-16 ジェンセット Ｄ−アミノ酸オキシダーゼおよびｄ−アスパラギン酸オキシダーゼのアンタゴニストを使用するｃｎｓ障害の処置
US20030166554A1 (en) 2001-01-16 2003-09-04 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
WO2002056823A2 (en) 2001-01-18 2002-07-25 Arnold Hoffman Redox therapy for tumors
ES2266084T3 (es) 2001-02-14 2007-03-01 Forte Iq B.V. Composicion farmaceutica que comprende una goma de xantano.
US7312247B2 (en) 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
CA2442366C (en) 2001-03-27 2012-09-25 Circagen Pharmaceutical, Llc Histone deacetylase inhibitors
US6495719B2 (en) 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US8026280B2 (en) 2001-03-27 2011-09-27 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
DE60113645T2 (de) 2001-04-10 2006-07-06 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Verwendung von Histonedeacetylasehemmern zur Behandlung von Papillomaviren assoziierte Krankheiten
US20040142859A1 (en) 2002-05-02 2004-07-22 Steffan Joan S. Method for treating neurodegenerative, psychiatric, and other disorders with deacetylase inhibitors
EP1390491B1 (de) 2001-05-02 2008-07-16 The Regents of the University of California Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren
US6372938B1 (en) 2001-05-21 2002-04-16 Stanislaw R. Burzynski Synthesis of 4-phenylbutyric acid
EP1291015A1 (de) 2001-09-10 2003-03-12 Lunamed AG Darreichungsformen mit verlängerter Wirkstofffreisetzung
JP2005526024A (ja) 2002-02-08 2005-09-02 スミスクライン ビーチャム コーポレーション インスリン分泌を阻害するための化合物及びそれに関連する方法
AU2003226014A1 (en) 2002-03-28 2003-10-13 Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease

Also Published As

Publication number Publication date
EP1427396A1 (de) 2004-06-16
ES2339536T3 (es) 2010-05-21
US7611729B2 (en) 2009-11-03
CN1553799A (zh) 2004-12-08
JP2005508901A (ja) 2005-04-07
ATE455539T1 (de) 2010-02-15
WO2003022253A1 (de) 2003-03-20
CN100508965C (zh) 2009-07-08
AU2002322964B2 (en) 2008-10-16
US20040180962A1 (en) 2004-09-16
HK1071847A1 (en) 2005-08-05
EP1427396B1 (de) 2010-01-20
EP1291015A1 (de) 2003-03-12
PT1427396E (pt) 2010-04-14
DK1427396T3 (da) 2010-05-25
CA2459165C (en) 2011-07-19
CA2459165A1 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
HK1071847A1 (en) Dosage forms having prolonged active ingredient release
JP2006501240A5 (de)
ZA200408649B (en) Opthamological use of roflumilast for the treatment of diseases of the eye
DK0759757T3 (da) Orale, væskeformige alendronatformuleringer
CA2326517A1 (en) New galenic preparations of meloxicam for oral administration
DK1333880T3 (da) Indretninger med coatede mikrofremspring til medikamentafgivelse gennem huden
PT1326613E (pt) Utilizacao de derivados de imidazo[1,2-a]piridin-,imidazo[1,2-a]pirimidin- e imidazo[1,2-a]pirazin-3-il-amina substituidos para a fabricacao de medicamentos para inibicao de nos
RU98111594A (ru) Фармацевтические композиции, включающие флурбипрофен
WO2006056711A3 (fr) Medicament oral a liberation modifiee d'au moins un principe actif sous forme multimicrocapsulaire
EA200300046A1 (ru) Быстро увеличивающаяся в объеме композиция для удерживания и контролированного выделения терапевтических агентов в желудке и лекарственные формы, включающие композицию
CA2503810A1 (en) Therapeutic agent for fibromyalgia
JP2002526407A5 (de)
RU2002121546A (ru) Вещества, предназначенные для лечения псориаза
JP2003514025A5 (de)
JP2004002429A5 (de)
JP2002540148A5 (de)
JP2002537246A5 (de)
RU2002129298A (ru) Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера
MXPA02009603A (es) Terapias de dosis divididas con actividad de deterioro vascular.
CA2474703A1 (en) Therapeutic agent of glaucoma comprising bunazosin and prostaglandins
CA2515259A1 (en) Use of acetylsalicylic acid for the treatment of hemorrhoidal disease
RU2005131943A (ru) Лечебные и/или профилактические средства для хронических болезней кожи
EP1297838A4 (de) Pralmorelin-haltige nasentropfen-präparate
SI1242062T1 (en) Anhydrous gel comprising nsaid for topical administration to the oral cavity
WO2008079818A3 (en) Intravenous administration of water soluble analgesic formulations

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: PETERS, H., DIPL.-BIOCHEM. DR.RER.NAT., PAT.-ANW.,

8364 No opposition during term of opposition